• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Possible Option in Opioid-Related Harm Reduction

A Possible Option in Opioid-Related Harm Reduction

August 6, 2020
Greg Sazima, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Greg Sazima, MD Dr. Sazima has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Oviedo-Joekes E et al, JAMA Psychiatry 2016;73(5):447–455

We have effective FDA-approved medications for opioid use disorder (OUD): buprenorphine, methadone, and injectable naltrexone. Yet some patients with severe OUD decline these options. Many other countries offer a more controversial treatment—medically supervised IV administration of diacetylmorphine, the active ingredient in heroin. Six randomized trials have endorsed the effectiveness of this approach, but diacetylmorphine is not available in North America for regulatory/legal reasons. Investigators at Providence Health Care in Vancouver, BC, designed a study to determine if injectable hydromorphone (Dilaudid) may be as effective as diacetylmorphine in reducing illicit opioid use.

In a double-blind trial, investigators randomized participants who were injecting heroin illicitly (n = 202) to either hydromorphone or diacetylmorphine for 6 months of up to thrice-daily supervised treatment. The outcome measures were self-reported illicit heroin use, self-reported street opioid use, and urine toxicology.

The results suggested non-inferiority for hydromorphone in the per-protocol analysis. Individuals offered hydromorphone were just as unlikely to report street heroin use as those offered diacetylmorphine (odds ratio -1.44, 90% confidence interval [CI] -3.22–0.27), and the same was the case for report of any illicit opioid use (odds ratio -0.15, 90% CI -2.09–1.76). The study included two other hopeful findings. First, participants weren’t able to distinguish between hydromorphone and diacetylmorphine in terms of the high they felt, implying that hydromorphone may be a successful substitution for heroin. Second, hydromorphone was safer than diacetylmorphine, with only 5 severe adverse events (SAEs) and 3 overdoses for the former, versus 24 SAEs and 11 overdoses for the latter.

CATR’s TAKE
This study provides hopeful evidence of IV hydromorphone as a clinically comparable, perhaps safer alternative for those patients who do not succeed in or engage with other medications for OUD. It offers a new option for harm reduction in this difficult-to-treat population.
Addiction Treatment
KEYWORDS harm-reduction heroin opioid-epidemic opioid-use-disorder pharmacology
Greg Sazima, MD

A New Proposal for SSRI Withdrawal

More from this author
www.thecarlatreport.com
Issue Date: August 6, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Opioid Use Disorder Treatment, CATR, July/August 2020
Note From the Editor-in-Chief
“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine
Telemedicine for Addiction Treatment: Evidence and Implementation Strategies
Updated Guidelines for Treating Opioid Use Disorder
A Possible Option in Opioid-Related Harm Reduction
Efficacy and Acceptability of Varenicline for Alcohol Use Disorder
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.